A History of Treatments for Myasthenia Gravis

John Carl Keesey

doi:10.1055/s-2004-829584

Seminars in Neurology, Table of Contents

Semin Neurol 2004; 24(1): 5-16
DOI: 10.1055/s-2004-829584

A History of Treatments for Myasthenia Gravis

John Carl Keesey¹

¹Department of Neurology, School of Medicine, University of California, Los Angeles, California

Abstract

Much of the improvement in the treatment of myasthenia gravis (MG) over the past 125 years can be attributed to the effectiveness of general medical measures such as advances in respiratory care and the discovery of antibiotics. Although MG became the model of an antibody-mediated autoimmune disease in the 1970s (the most documented antigen being the muscle acetylcholine receptor at the neuromuscular junction), the pathogenesis of MG has not been the rationale for most treatments found to be useful for this disease. The serendipitous benefit of anticholinesterases for MG in the 1930s subsequently focused attention on the neuromuscular junction. The beginnings of the controversy over thymectomy for MG in the 1940s and 1950s preceded the discovery in 1960 of the function of the thymus. Before the autoimmune pathogenesis of MG was known, adrenocorticotropic hormone (ACTH) and steroids for MG were tried for reasons that turned out to be incorrect. Further immunosuppressive treatments for MG were largely empirical, following their use in organ transplantation and other autoimmune diseases. More specific treatments, based on our knowledge of pathogenesis, are still experimental but hopefully will be the history of the future.

KEYWORDS

History - myasthenia - treatment

Full Text

References

REFERENCES

1 Keesey J. Myasthenia Gravis, An Illustrated History. Roseville, CA; Publishers Design Group 2002
2 Erb W H. Handbook of Electrotherapeutics. Pützel L, trans. New York; William Woods 1883
3 Viets H R. A historical review of myasthenia gravis from 1672 to 1900. JAMA. 1953; 153 1273-1280
4 Goldflam S. Ueber einen scheinbar heilbaren bulbärparalytischen symptomencomplex mit betheiligung der extremitäten. Deutsche Z Nervenheilkunde. 1893; 4 312-352
5 Goldflam S. Weiteres uber die asthenische lahmung nebst einem obductionsbefund. Neurologishes Zentralblatt 1902 21 97-107 490-496
6 Oppenheim H. Die Myasthenische Paralyse (Bulbärparalyse ohne anatomischen Befund. Berlin; S. Karger 1901
7 Campbell H, Bramwell E. Myasthenia gravis. Brain. 1900; 23 277-336
8 Starr M A. Myasthenia gravis. J Nerv Ment Dis. 1912; 39 721-731
9 Oppenheim H. Weitere beitrag sur lehre von den acuten, night-eitrigen encephalitis und der poliencephalomyelitis. Deutsche Z Nervenheilkunde. 1899; 15 1-21
10 Weigert C. Pathologisch-anatomischer Beitrag zur Erb'schen Krankheit (Myasthenia gravis). Neurologisches Zentralblatt. 1901; 20 596-601
11 Schumacher C H, Roth P. Thymektomie bei einem Fall von Murbus Basedowi mit Myasthenia. Mitteilungen Grensgebeiten Medizin Chirurgie. 1913; 25 746-765
12 Keschner M, Strauss I. Myasthenia gravis. AMA Arch Neurol Psychiatry. 1927; 17 337-376
13 Kennedy F S, Moersch F P. Myasthenia gravis: a clinical review of eighty-seven cases observed between 1915 and early part of 1932. Can Med Assoc J. 1935; 37 216-223
14 Shaw L E. A case of bulbar paralysis without structural changes in the medulla. Brain. 1890; 13 96-99
15 Goerig M, Filos K, Ayisi K W. George Edward Fell and the development of respiratory machines. In: Atkinson RS, Boulton TB The History of Anesthesia. Park Ridge, NJ; Parthenon Publishing Group 1987: 386-393
16 Drinker P, McKhann C F. The use of a new apparatus for the prolonged administration of artificial respiration. JAMA. 1929; 92 1658-1660
17 Secher O. The polio epidemic in Copenhagen 1952. In: Atkinson RS, Boulton TB The History of Anesthesia. Park Ridge, NJ; Parthenon Publishing Group 1987: 425-432
18 Remen L. Zur pathogenese und therapie der myasthenia gravis pseudoparalytica. Deutsche Z Nervenheilkunde. 1932; 128 66-78
19 Boothby W M, Adams M, Power M H et al.. Myasthenia gravis: second report on the effect of treatment with glycine. Mayo Clin Proc. 1932; 7 737-756
20 Walker M B. Treatment of myasthenia gravis with physostigmine. Lancet. 1934; 1 1200-1201
21 Keesey J C. Contemporary opinions about Mary Walker, a shy pioneer of therapeutic neurology. Neurology. 1998; 51 1433-1439
22 Everts W H. The treatment of myasthenia gravis by the oral administration of Prostigmin. Bull Neurol Inst. 1935; 4 523-530
23 Viets H R. Myasthenia gravis. JAMA. 1945; 127 1089-1096
24 Eaton L M. Care of the patient who has myasthenia gravis. Med Clin North Am. 1947; 31 907-923
25 Keesey J C. “Crisis” in myasthenia gravis: an historical perspective. Muscle Nerve. 2002; 26 1-3
26 Laurent L PE, Walther W W. The influence of large doses of potassium chloride on myasthenia gravis. Lancet. 1935; 1 1434-1435
27 Minot A S, Dodd K, Riven S S. Use of guanidine hydrochloride in treatment of myasthenia gravis. JAMA. 1939; 113 553-559
28 Blalock A, Mason M F, Morgan H J, Riven S S. Myasthenia gravis and tumors of the thymic region: report of a case in which the tumor was removed. Ann Surg. 1939; 110 544-561
29 Blalock A, Harvey A M, Ford F R, Lilienthal J L. The treatment of myasthenia gravis by removal of the thymus gland: preliminary report. JAMA. 1941; 117 1529-1533
32 Clagett O T, Eaton L M. Surgical treatment of myasthenia gravis. J Thorac Surg. 1947; 16 62-80
30 Kirschner P A. Alfred Blalock and thymectomy for myasthenia gravis. Ann Thorac Surg. 1987; 43 348-349
31 Keynes G. The results of thymectomy in myasthenia gravis. BMJ. 1949; 1 611-616
33 Eaton L M, Clagett O T. Thymectomy in the treatment of myasthenia gravis. Results in seventy-two cases compared to one hundred and forty-two control cases. JAMA. 1950; 142 963-967
34 Eaton L M, Clagett O T. Present status of thymectomy in treatment of myasthenia gravis. Am J Med. 1955; 19 703-717
35 Givel J C. Historical review. In: Givel JC Surgery of the Thymus. Berlin; Springer-Verlag 1990: 1-9
36 Schwab R S, Leland C C. Sex and age in myasthenia gravis as critical factors in incidence and remission. JAMA. 1953; 153 1270-1280
37 Grob D. Myasthenia gravis, current status of pathogenesis, clinical manifestations, and management. J Chronic Dis. 1958; 8 536-566
38 Perlo V P, Poskanzer D C, Schwab R S, Viets H R, Osserman K E, Genkins G. Myasthenia gravis: evaluation of treatment in 1,355 patients. Neurology. 1966; 16 431-439
39 Bernatz PE in discussion following Buckingham JM . Howard F M, Bernatz P E, Payne W S, Harrison E G, O'Brien P C, Weiland L H. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg. 1976; 184 453-458
40 Kirschner P A. The history of surgery of the thymus gland. Chest Surg Clin N Am. 2000; 10 153-165
41 Osserman K E, Teng P, Kaplan L I. Studies in myasthenia gravis. Preliminary report on therapy with Mestinon bromide. JAMA. 1954; 155 961-965
42 Comroe J H, Todd J, Gammon G D et al.. The effect of di-isopropyl-fluorophosphate (DFP) upon patients with myasthenia gravis. Am J Med Sci. 1946; 212 641-651
43 Westerberg M R, Luros J T. The clinical use of hexaethyl tetraphosphate in myasthenia gravis. Med Bull (Ann Arbor). 1948; 14 15-17
44 Burgen A SV, Keel C A, McAlpine D. Tetra-ethylpyrophosphate in myasthenia gravis. Lancet. 1948; 1 519-521
45 Rider J A, Schulman S, Richter R B, Moeller H C, DuBois K P. Treatment of myasthenia gravis with octamethyl phyrophosphoramide. JAMA. 1951; 145 967-972
46 Artusio J F, Riker W F, Wescoe W C. Studies on the inter-relationship of certain cholinergic compounds. IV. Anti-curare action in anesthetized man. J Pharmacol Exp Ther. 1950; 100 227-237
47 MacFarlane D W, Pelikan W e, Unna K R. Evaluation of curarizing drugs in man. V. Antagonism to curarizing effects of d-tubocurarine by neostigmine, m-hydroxy phenyltrimethylammonium and m-hydroxy phenylethyldimethylammonium. J Pharmacol Exp Ther. 1950; 100 382-392
48 Westerberg M R, Magee K R, Shideman F E. Effect of 3-hydroxy phenyldimethylethyl ammonium chloride (Tensilon) in myasthenia gravis. Med Bull (Ann Arbor). 1951; 17 311-316
49 Westerberg M R, Magee K R, Shideman F E. Effect of Tensilon in myasthenia gravis. Neurology. 1953; 3 302-305
50 Tether J E. Mestinon in myasthenia gravis (preliminary report). Dis Nerv Syst. 1954; 15 227-231
51 Schwab R S, Timberlake W H. Pyridostigmin (Mestinon) in the treatment of myasthenia gravis. N Engl J Med. 1954; 251 271-272
52 Westerberg M R, Magee K R. Mestinon in the treatment of myasthenia gravis. Neurology. 1954; 4 762-771
53 Schwab R S. WIN 8077 in the treatment of sixty myasthenia gravis patients, a twelve-month report. Am J Med. 1955; 19 734-736
54 Westerberg M R. Clinical evaluation of ambenonium (Mysuran) chloride. AMA Arch Neurol Psychiatry. 1956; 75 91-94
55 Kraupp O, Stumpf C, Herzfeld E, Pillat B. Pharmakologische Eigenschaften einiger langwirksamer Cholinesterase-Hemmkörper aus der Reihe der Polymethylen-bis-(Carbaminoyl-m-Trimethylammoniumphenole). Arch Int Parmacodyn Ther. 1955; 102 281-303
56 Pateisky K, Herzfeld E, Stumpf C. Der Effekt von Polymethylen-bis-(N-methyl-m- trimethylammonium-phenolen) BC40, BC47, BC58 auf Cholinesteraseaktivität und Muskeltätigkeit bei Myasthenia gravis pseudparalytica. Wein KlinWochenschr. 1957; 69 2-7
57 Hoefer P FA, Aronow H, Rowland L P. Long-acting compounds, especially BC 51, in the treatment of myasthenia gravis. In: Viets HR Myasthenia Gravis. The Second International Symposium Proceedings Springfield, IL; Charles C. Thomas 1961: 545-555
58 Schwarz H. Urecholine in myasthenia gravis. Can Med Assoc J. 1955; 72 346-351
59 Gottlieb B, Laurent L PE. Spironolactone in the treatment of myasthenia gravis. Lancet. 1961; 2 528-529
60 Satoyoshi E, Murakami K, Okazaki T. Triamterene in the treatment of myasthenia gravis. Lancet. 1964; 15 741-742
61 Somers J E, Irwin R L, Shy G M. The use of lycoramine derivatives in myasthenia gravis. Neurology. 1963; 13 543-553
62 Foldes F F, Foldes V M, McNall P G. The use of echothiophate in myasthenia gravis. Clin Pharmacol Ther. 1966; 7 620-630
63 Hofmann W W. Action of veratrine on human skeletal muscle with special reference to myasthenia gravis. Neurology. 1958; 8 417-432
64 Flacke W, Caviness V S, Samaha F G. Treatment of myasthenia gravis with germine diacetate. N Engl J Med. 1966; 275 1207-1214
65 Marsh D O. Adrenal therapy for neuromuscular disease including myasthenia gravis from 1896. N Y State J Med. 1974; 74 1974-1976
66 Simon H E. Myasthenia gravis, effect of treatment with anterior pituitary extract: preliminary report. JAMA. 1935; 104 2065-2066
67 Schlezinger N S. Evaluation of therapy in myasthenia gravis. Arch Intern Med. 1940; 65 60-77
68 Torda C, Wolff H G. Effects of adrenocorticotrophic hormone on neuro-muscular function in patients with myasthenia gravis. Proc Soc Exp Biol Med. 1949; 71 432-435
69 Millikan C H, Eaton L M. Clinical evaluation of ACTH and cortisone in myasthenia gravis. Neurology. 1951; 1 145-152
70 Grob D, Harvey A M. Effect of adrenocorticotropic hormone (ACTH) and cortisone administration in patients with myasthenia gravis, and report on onset of myasthenia gravis during prolonged cortisone administration. Bull Johns Hopkins Hosp. 1952; 91 124-136
71 Freydberg L D. The place of corticotrophin in the treatment of myasthenia gravis. Ann Intern Med. 1960; 52 806-818
72 Schlezinger N S. Present status of therapy in myasthenia gravis. JAMA. 1952; 148 508-513
73 Osserman K E. Myasthenia Gravis. New York; Grune & Stratton 1958: 159
74 von Reis G, Liljestrand Å, Matell G. Results with ACTH and spironolactone in severe cases of myasthenia gravis. Acta Neurol Scand Suppl. 1965; 13 463-471
75 Simpson J. Myasthenia gravis: a new hypothesis. Scott Med J. 1960; 5 419-436
76 Osserman K E, Genkins G. Studies in myasthenia gravis. Short-term massive corticotrophin therapy. JAMA. 1966; 198 699-702
77 Grob D, Namba T. Corticotrophin in generalized myasthenia gravis. Effect of short, intensive courses. JAMA. 1966; 198 703-707
78 Thevènard A. Carotid sinus denervation in myasthenia gravis. In: Viets HR Myasthenia Gravis. The Second International Symposium Proceedings Springfield, IL; Charles C Thomas 1961: 624-633
79 Kjaer M. Myasthenia gravis and myasthenic syndromes treated with prednisone. Acta Neurol Scand. 1971; 47 464-474
80 Warmolts J R, Engel W K. Benefit from alternate-day prednisone in myasthenia gravis. N Engl J Med. 1972; 286 17-20
81 Jenkins R B. Treatment of myasthenia gravis with prednisone. Lancet. 1972; 1 765-767
82 Shy G M, Brendler S, Rabinovitch R, McEachern D. Effects of cortisone in certain neuromuscular disorders. JAMA. 1950; 144 1353-1358
83 Strauss A JL, Seegal B C, Hsu K C, Burkholder P M, Nastuk W L, Osserman K E. Immunofluorescence demonstration of a muscle binding, complement fixing serum globulin fraction in myasthenia gravis. Proc Soc Exp Biol Med. 1960; 105 184-191
84 Miller J FAP. Immunological function of the thymus. Lancet. 1961; 2 748-749
85 Wolf S M, Rowland L P, Schotland D L, McKinney A S, Hoefer P FA, Aranow H. Myasthenia as an autoimmune disease. Clinical aspects. Ann N Y Acad Sci. 1966; 135 517-535
86 Rowland L P. Immunosuppressive drugs in treatment of myasthenia gravis. Ann N Y Acad Sci. 1971; 183 351-357
87 Delwaide P J, Salmon J, van Cauwenberger H. Premiers essais de traitement de la myasthenia par azathioprine. Acta Neurol Psychiatr Belg. 1967; 67 701-712
88 Guille-Minault C. Premiers essais de traitement de la myasthenia par azathioprine. Gaz Med Fr. 1968; 75 6545
89 Mertens H G, Balzereit F, Leipert M. The treatment of severe myasthenia gravis with immunosuppressive agents. Eur Neurol. 1969; 2 321-339
90 Hertel G, Mertens H G, Reuther P, Ricker K. The treatment of myasthenia gravis with azathioprine. In: Dau PC Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA; Houghton Mifflin 1979: 315-328
91 Matell G, Bergström K, Franksson C et al.. Effects of some immunosuppressive procedures on myasthenia gravis. Ann N Y Acad Sci. 1976; 274 659-676
92 Szobor A, Petrányi G. Immunosuppressive therapy of myasthenia gravis. Acta Med Acad Sci Hung. 1970; 27 397-411
93 Nouza K, Šmat V. The favourable effect of cyclophosphamide in myasthenia gravis. Rev Fr Etud Clin Biol. 1968; 13 161-163
94 Perez M C, Buot W L, Mercado-Danguilan C, Bababaldo Z G, Renales L D. Stable remission in myasthenia gravis. Neurology. 1981; 31 32-37
95 Goulon M, Elkharrat D, Gajdos P, Lokiec F, Morel E. Preliminary results in myasthenia gravis treated with cyclosporin. Ann N Y Acad Sci. 1987; 505 857-860
96 Tindall R SA, Rollins J A, Phillips J T, Greelee R G, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987; 316 719-724
97 Nyberg-Hansen R, Gjerstad L. Myasthenia gravis treated with cyclosporin. Acta Neurol Scand. 1988; 77 307-313
98 Hauser R A, Malek A R, Rosen R. Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil. Neurology. 1998; 51 912-913
99 Chaudhry V, Cornblath D R, Griffin J W, O'Brien R, Drachman D B. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001; 56 94-96
100 Ciafaloni E, Massey J M, Tucker-Lipscomb B, Sanders D B. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology. 2001; 56 97-99
101 Riven S S, Mason M F. The treatment of myasthenia gravis. South Med J. 1937; 30 181-190
102 Aring C D. Treatment of myasthenia gravis with the Roentgen ray. Ohio State Med J. 1943; 39 241-244
103 Keynes G. Investigations into thymic disease and tumour formation. Br J Surg. 1955; 42 449-462
104 Grob D. Course and management of myasthenia gravis. JAMA. 1953; 153 529-532
105 Henson R A, Stern G A, Thompson V C. Thymectomy for myasthenia gravis. Brain. 1965; 88 11-28
106 Schwab R S. Evaluation of one hundred and thirty thymectomies. In: Viets HR Myasthenia Gravis. The Second International Symposium Proceedings Springfield, IL; Charles C Thomas 1961: 597-601
107 Schulz M D, Schwab R S. Results of thymic (mediastinal) irradiation in patients with myasthenia gravis. Ann N Y Acad Sci. 1971; 183 303-307
108 Philllips T L, Buschke F. The role of radiation therapy in myasthenia gravis. Calif Med. 1967; 106 282-289
109 Currier R D, Routh A, Hickman B T, Douglas M A. Thymus irradiation for myasthenia gravis. Radiology. 1983; 146 199-201
110 Engel W K, Lichter A S, Dalakas M. Spenic and total-body irradiation treatment of myasthenia gravis. Ann N Y Acad Sci. 1981; 377 744-754
111 Durelli L, Ferrio M F, Urgesi A, Poccardi G, Ferrero B, Bergamini L. Total body irradiation for myasthenia gravis: a long-term follow-up. Neurology. 1993; 43 2215-2221
112 Stricker E, Thölen H, Massini M A, Stauf H. The effect of haemodialysis in myasthenia gravis. J Neurol Neurosurg Psychiatry. 1960; 23 291-294
113 Hedger R W, Davis F A, Schwartz F D, Ing T S. Improvement of myasthenia gravis by hemodialysis in a patient with chronic renal failure. Ann Intern Med. 1971; 75 749-752
114 Patten B M. A hypothesis to account for the Mary walker phenomenon. Ann Intern Med. 1975; 82 411-415
115 Lefvert A K, Matell G. Thoracic duct lymph drainage in myasthenia gravis: clinical effect and kinetic studies of the acetylcholine receptor antibody. In: Dau PC Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA; Houghton Mifflin 1979: 151-160
116 Tindall S C, Peters B H, Caverley J R, Sarles H E, Fish J C. Thoracic duct lymphocyte depletion in myasthenia gravis. Arch Neurol. 1973; 29 202-203
117 Bergstrom K, Franksson C, Matell G et al.. Drainage of thoracic duct lymph in twelve patients with myasthenia gravis. Eur Neurol. 1975; 13 19-30
118 Lindstrom J M, Seybold M E, Lennon V A, Whittingham S, Duane D D. Antibody to acetylcholine receptor in myasthenia gravis. Neurology. 1976; 26 1054-1059
119 Pinching A F, Peters D K, Newsom-Davis J. Remission of myasthenia gravis following plasma exchange. Lancet. 1976; 2 1373-1376
120 Dau P C, Lindstrom J M, Cassel C K, Denys E H, Shev E E, Spitler L E. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. N Engl J Med. 1977; 297 1134-1140
121 Pirofsky B, Reid R H, Bardana E J, Baker R L. Antithymocyte antiserum therapy in myasthenia gravis. Postgrad Med J. 1976; 52(suppl 5) 112-117
122 Pirofsky B, Reid R H, Bardana E J, Baker R L. Myasthenia gravis treated with purified antithymocyte antiserum. Neurology. 1979; 29 112-116
123 Leövey A, Szobor A, Szegedi G, Szathmáry I, Petrányi G. Myasthenia gravis: ALG treatment of seriously ill patients. Eur Neurol. 1975; 13 422-432
124 Genkins G, Paptestas A E, Kornfeld P, Horowitz S H. Studies in myasthenia gravis: staging and gamma globulin. In: Dau PC Plasmapheresis and the Immunobiology of Myasthenia Gravis. Boston, MA; Houghton Mifflin 1979: 144-150
125 Gajdos P, Outin H, Elkharrat D et al.. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet. 1984; 1 406-407
126 Arsura E L, Bick A, Brunner N G, Namba T, Grob D. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med. 1986; 146 1365-1368

John KeeseyM.D.

1144 Iliff Street

Pacific Palisades, CA 90272